CareDx, Inc. (NASDAQ:CDNA) Director Peter Maag Sells 10,000 Shares

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Peter Maag sold 10,000 shares of the stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $18.58, for a total transaction of $185,800.00. Following the completion of the sale, the director directly owned 308,846 shares in the company, valued at approximately $5,738,358.68. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Peter Maag also recently made the following trade(s):

• On Tuesday, June 17th, Peter Maag sold 10,000 shares of CareDx stock. The stock was sold at an average price of $19.24, for a total transaction of $192,400.00.
• On Wednesday, April 30th, Peter Maag sold 13,281 shares of CareDx stock. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63.

CareDx Stock Performance

Shares of NASDAQ:CDNA traded down $0.50 during trading hours on Friday, hitting $20.13. 1,339,105 shares of the company's stock traded hands, compared to its average volume of 927,375. CareDx, Inc. has a 52 week low of $14.09 and a 52 week high of $34.84. The company's fifty day simple moving average is $18.09 and its two-hundred day simple moving average is $19.69. The company has a market cap of $1.12 billion, a price-to-earnings ratio of 17.50 and a beta of 2.19.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.03. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The company had revenue of $84.69 million during the quarter, compared to analyst estimates of $84.56 million. During the same quarter last year, the firm posted ($0.03) EPS. The business's revenue for the quarter was up 17.6% on a year-over-year basis. On average, analysts anticipate that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

Hedge Funds Weigh In On CareDx

Several large investors have recently made changes to their positions in CDNA. Sterling Capital Management LLC boosted its holdings in shares of CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after buying an additional 1,126 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after buying an additional 3,322 shares during the period. State of Wyoming acquired a new position in shares of CareDx in the fourth quarter worth about $91,000. PNC Financial Services Group Inc. boosted its holdings in shares of CareDx by 20,200.0% in the first quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock worth $79,000 after buying an additional 4,444 shares during the period. Finally, Morse Asset Management Inc acquired a new position in shares of CareDx in the first quarter worth about $103,000.

Analyst Upgrades and Downgrades

Several research firms have commented on CDNA. Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. HC Wainwright reissued a "neutral" rating and set a $25.00 target price on shares of CareDx in a research note on Monday, May 5th. The Goldman Sachs Group lowered their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Finally, Stephens reissued an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.